GENV-002 was invented by Dwight Koeberl, M.D., Ph.D., professor in the Department of Pediatrics and a medical genetics specialist at Duke University, along with leading experts in genetic disease and specifically Pompe disease.
For more information please click the link below:
https://otc.duke.edu/news/geneventiv-announces-global-licensing-agreement-for-universal-gene-editing-therapy-for-infantile-onset-and-late-onset-pompe-disease/
Exclusive gene editing license for infantile and late onset Pompe disease
Posted On: 18/04/2025
- Categories:
- Industry
- News
- Gene Editing
A gene therapy company GeneVentiv Therapeutics announced that it has signed a global licensing agreement with Duke University for the first universal gene editing therapy for both infantile and late onset Pompe disease. The therapy has been designated GENV-002.